中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
The Chinese Journal of Clinical Pharmacology
2015年
17期
1745-1748
,共4页
肖成燕%朱毅%董志%封沙%向丽
肖成燕%硃毅%董誌%封沙%嚮麗
초성연%주의%동지%봉사%향려
水黄皮%水黄皮胶囊%抗血栓作用%机制
水黃皮%水黃皮膠囊%抗血栓作用%機製
수황피%수황피효낭%항혈전작용%궤제
Pongamia pinnata%Pongamia pinnata capsules%antithrombotic effects%mechanism
目的:研究水黄皮胶囊剂的抗血栓作用并从抗凝、纤溶两个方面初步探讨其作用机制。方法制备小鼠断尾出血、小鼠尾血栓、大鼠下腔静脉血栓3种模型,小鼠随机分为5组(每组8只):空白组(0.9%NaCl )或模型组(0.5%CMC-Na)、阳性对照组(阿司匹林100 mg· kg-1)、水黄皮胶囊剂高、中、低3个剂量组(900,300,100 mg· kg-1)。大鼠随机分为6组(每组8只):假手术组(0.9%NaCl)、模型组(0.5%CMC -Na )、阳性对照组(阿司匹林50 mg· kg-1)、水黄皮胶囊剂高、中、低3个剂量组(450,150,50 mg· kg-1),每天灌胃1次,连续15 d。光镜下观察大鼠下腔静脉的病理变化,并测定大鼠血浆凝血酶原时间( PT)、活化部分凝血活酶时间( APTT)以及组织型纤溶酶原激活剂(t-PA)和纤溶酶原激活物抑制因子1(PAI-1)水平。结果水黄皮胶囊剂能明显延长PT和APTT时间,升高血浆t-PA 活性、降低PAI-1活性。结论水黄皮胶囊剂有显著抗血栓作用,其作用机制可能与抗凝系统和纤溶系统活性升高有关。
目的:研究水黃皮膠囊劑的抗血栓作用併從抗凝、纖溶兩箇方麵初步探討其作用機製。方法製備小鼠斷尾齣血、小鼠尾血栓、大鼠下腔靜脈血栓3種模型,小鼠隨機分為5組(每組8隻):空白組(0.9%NaCl )或模型組(0.5%CMC-Na)、暘性對照組(阿司匹林100 mg· kg-1)、水黃皮膠囊劑高、中、低3箇劑量組(900,300,100 mg· kg-1)。大鼠隨機分為6組(每組8隻):假手術組(0.9%NaCl)、模型組(0.5%CMC -Na )、暘性對照組(阿司匹林50 mg· kg-1)、水黃皮膠囊劑高、中、低3箇劑量組(450,150,50 mg· kg-1),每天灌胃1次,連續15 d。光鏡下觀察大鼠下腔靜脈的病理變化,併測定大鼠血漿凝血酶原時間( PT)、活化部分凝血活酶時間( APTT)以及組織型纖溶酶原激活劑(t-PA)和纖溶酶原激活物抑製因子1(PAI-1)水平。結果水黃皮膠囊劑能明顯延長PT和APTT時間,升高血漿t-PA 活性、降低PAI-1活性。結論水黃皮膠囊劑有顯著抗血栓作用,其作用機製可能與抗凝繫統和纖溶繫統活性升高有關。
목적:연구수황피효낭제적항혈전작용병종항응、섬용량개방면초보탐토기작용궤제。방법제비소서단미출혈、소서미혈전、대서하강정맥혈전3충모형,소서수궤분위5조(매조8지):공백조(0.9%NaCl )혹모형조(0.5%CMC-Na)、양성대조조(아사필림100 mg· kg-1)、수황피효낭제고、중、저3개제량조(900,300,100 mg· kg-1)。대서수궤분위6조(매조8지):가수술조(0.9%NaCl)、모형조(0.5%CMC -Na )、양성대조조(아사필림50 mg· kg-1)、수황피효낭제고、중、저3개제량조(450,150,50 mg· kg-1),매천관위1차,련속15 d。광경하관찰대서하강정맥적병리변화,병측정대서혈장응혈매원시간( PT)、활화부분응혈활매시간( APTT)이급조직형섬용매원격활제(t-PA)화섬용매원격활물억제인자1(PAI-1)수평。결과수황피효낭제능명현연장PT화APTT시간,승고혈장t-PA 활성、강저PAI-1활성。결론수황피효낭제유현저항혈전작용,기작용궤제가능여항응계통화섬용계통활성승고유관。
Objective To study the antithrombotic effects of Pongamia pinnata capsules and to explore its mechanism from anticoagulat action and fibrinolysis.Methods Three experimental models , including mouse tail bleeding model , mouse tail thrombosis model and inferior vena cava thrombosis model were established.The mice were randomly divided into 5 groups(8 mice per group):blank or model group (0.5%CMC-Na), positive control group ( aspirin, 100 mg · kg -1 ) , Pongamia pinnata capsules of the high dose group , middle dose group and low dose group (in accordance with 900,300,100 mg· kg -1 ).The SD rats were ran-domly divided into 6 groups ( 8 mice per group ):sham group ( 0.9%NaCl), model group(0.5%CMC-Na), positive control group(aspirin, 50 mg· kg-1), Pongamia pinnata capsules of the high dose group , middle dose group and low dose group ( in accordance with 450 ,150 ,50 mg· kg -1 ), gavage once daily for 15 d.The pathological changes of inferior vena cava tissue were observed by light microscope.The pro-thrombin time ( PT),activated partial thromboplastin time ( APTT) and the contents of tissue type plasminogen activator ( t -PA ) and plasminogen activator inhibitor -1 ( PAI -1 ) were measured .Results The PT and APTT were significantly prolonged.The release of t -PA was promoted and the release of PAI -1 was inhibited. Conclusion There is a significant antithrombotic effects about Pongamia pinnata capsules and its mechanism may be related to increasing the activity of the anticoagulant factor and fibrinolysis system.